Specifically, the proportion of CoronaVac vaccinees harbouring S1-reactive IFNγ+CD4+T cells was significantly reduced in participants with type 2 diabetes (p=0.02) after adjustment for BMI. This evidence concerns the gene CD4 and type 2 diabetes mellitus.